While this is an old link it connects ... Looking specifically at the follicular lymphoma patients, 85% (38/44) evaluable FL patients achieved a complete response. http://www.news-medical.net/news/20110618/Celgene-announces-data-from-REVLIMID-plus-rituximab-Phase-II-study-on-malignant-lymphomas.aspx